Embarazo y nuevo coronavirus: Experiencia global reportada

P, Rogelio González; M, María Teresa Haye; A, Alfredo M Germain; B, Olivia Hernández; P, Jorge Gutiérrez; S, Jyh-Kae Nien; M, Ricardo Gómez; P, Juan Kusanovic; G, Andrés Pons; E, Enrique Oyarzún; A, Francisco Larraín; D, Horacio Figueroa; S, Hernán Muñoz; M, Carlos Díaz; M, Jorge Neira; N, Pedro Daza

doi:10.4067/s0717-75262020000700016

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dentro de las manifestaciones gastrointestinales más comunes están náuseas, vómitos, malestar abdominal y diarrea. Esto se pudo corroborar con la investigación de Ortiz E et al en Colombia en el 2020, en la cual dieron a conocer que los síntomas más comunes en una gestante son malestar general (58,3 %), cefalea (37,5 %) fiebre (29,2 %), tos (25 %), dolor de garganta (16,7 %), diarrea (12,5 %), mialgia (8,3 %) y en menor proporción odinofagia, dificultad respiratoria y fatiga (5,11) .…”

Section: Discussionunclassified

See 1 more Smart Citation

Características clínicas y epidemiológicas de gestantes con COVID-19 hospitalizadas en un Hospital del Norte del Perú, 2020

Castillo-Silva,

Vilchez-Gamboa,

Becerra-Gutiérrez

2023

Rev Exp Med

View full text Add to dashboard Cite

Objective: To describe the clinical and epidemiological characteristics of pregnant women with COVID-19 hospitalized in a hospital in northern Peru from April to December 2020. Methods: Descriptive, observational, retrospective and cross-sectional study. The population consisted of all pregnant women hospitalized with a diagnosis of COVID-19. The collection was through indirectobservation, with the use of medical records and epidemiological records, then it was transferred to a collection record and processed in an Excel 2019 database. Results: 111 medical records were evaluated, the most frequent age range was between 18 to 35 years (70.3 %). 92 % of the patients were in the third trimester of pregnancy. The most frequent comorbidities were diabetes (25.7 %), arterialhypertension (20 %), obesity (17.1 %), chronic diseases (14.3 %), asthma (11.4 %), and hypothyroidism (11.4 %). Within the clinical manifestations, general malaise represented 58.3 %, headache 37.5 %, fever 29.2 %, fatigue 29.2 % and cough 25 %, likewise 78.4 % did not have any symptoms. 27 % of patients presented complications such as fetal death (30 %), premature labor (30 %), pneumonia (26.7 %), acute respiratory failure (10 %); of these, only 13.3 % were hospitalized in the ICU for COVID-19. Conclusions: COVID-19 in pregnant women presented a mild clinical picture, with common symptoms such as malaise, headache, fever, cough, and fatigue. The pregnant women did not have major complications, except those with comorbidities. And only 3.60% entered the ICU, there were no evidence of deaths.

show abstract

Section: Discussionunclassified

“…Hay cambios en la fisiología pulmonar, que son más pronunciados en la segunda mitad del embarazo. Debido al crecimiento del útero, el diafragma aumenta aproximadamente 4 cm, mientras que el consumo de oxígeno aumenta en un 20 % y la capacidad residual funcional disminuye significativamente (4,5) .…”

Section: Introductionunclassified

Características clínicas y epidemiológicas de gestantes con COVID-19 hospitalizadas en un Hospital del Norte del Perú, 2020

Castillo-Silva,

Vilchez-Gamboa,

Becerra-Gutiérrez

2023

Rev Exp Med

View full text Add to dashboard Cite

show abstract

Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has turned pregnant women’s healthcare into a worldwide public health challenge. Although initial data did not demonstrate pregnancy as a more susceptible period to severe outcomes of acute severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection, there are an increasing number of reports showing that not only pregnant women might be at significantly higher risk than non-pregnant women by COVID-19 but also the fetus. These findings may be related to adaptive changes that occur during pregnancy, such as the reduction in the residual respiratory capacity, the decrease in viral immune responses, and the increased risk for thromboembolic events. Additionally, despite the SARS-CoV-2 vertical transmission evidence being uncommon, maternal illness severity might reflect serious perinatal and neonatal outcomes. Thus, protecting the maternal–fetal dyad against COVID-19 is critical. Even though pregnant women initially were excluded from vaccine trials, several studies have provided safety and efficacy of the overall vaccine COVID-19 platforms. Vaccination during pregnancy becomes a priority and can generate benefits for both the mother and newborn: maternal neutralizing antibodies are transmitted through the placenta and breastfeeding. Moreover, regarding passive immunization, human milk contains other bioactive molecules and cells able to modulate the newborn’s immune response, which can be amplified after the vaccine. Nonetheless, many issues remain to be elucidated, considering the magnitude of the protective immunity transferred, the duration of the induced immunity, and the optimal interval for pregnant immunization. In this review, we assessed these unmet topics supported by literature evidence regarding the vaccine’s immunogenicity, pregnancy immune heterogeneity, and the unique human milk antiviral features.

show abstract

Embarazo y nuevo coronavirus: Experiencia global reportada

Cited by 2 publications

References 16 publications

Características clínicas y epidemiológicas de gestantes con COVID-19 hospitalizadas en un Hospital del Norte del Perú, 2020

Características clínicas y epidemiológicas de gestantes con COVID-19 hospitalizadas en un Hospital del Norte del Perú, 2020

Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic

Contact Info

Product

Resources

About